Watch IRLA. Know when insiders buy.
One email the day a filing lands. Free.
IRLA
IRulya Therapeutics Inc.
32.03
−1.20 −3.61%
USD · close Oct 16
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
—
not graded: no insider, short or call data yet
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $32.6MP/E —DIV YIELD —FCF YIELD -144.28%REV TTM —NET INCOME −$92.5MNET CASH $116M52W 16.00 – 880.00SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$79.8M | −$75.5M | — | -12.31 | −$18.9M | $0 | −$18.9M | Aug 14 |
| Q1 2026 · Mar 31 | — | — | — | −$14.6M | $35.9M | — | 2.88 | −$7.6M | $0 | −$7.6M | May 11 |
| Q4 2025 · Dec 31derived | — | — | — | −$19.4M | −$39.5M | — | -0.76 | −$10.5M | $4K | −$10.5M | Apr 10 |
| Q3 2025 · Sep 30 | — | — | — | −$13.4M | −$13.4M | — | -0.25 | −$9.9M | $74K | −$10M | Nov 12 |
| Q2 2025 · Jun 30 | — | — | — | −$10.4M | −$16M | — | -68.75 | −$11.4M | $126K | −$11.5M | Aug 14 |
| Q1 2025 · Mar 31 | — | — | — | −$14.9M | −$15M | — | -3.42 | −$9.6M | $148K | −$9.7M | May 11 |
| Q4 2024 · Dec 31derived | — | — | — | −$12M | −$12.5M | — | -0.28 | −$7.6M | $133K | −$7.7M | Apr 10 |
| Q3 2024 · Sep 30 | — | — | — | −$5.9M | −$5.5M | — | -0.13 | −$7.3M | $46K | −$7.3M | Nov 12 |
| Q2 2024 · Jun 30 | — | — | — | −$28.2M | −$27.7M | — | -0.64 | −$8.7M | $39K | −$8.8M | Aug 11 |
| Q1 2024 · Mar 31 | — | — | — | −$11.2M | −$11.1M | — | -0.26 | −$8.4M | $39K | −$8.4M | May 13 |
| Q4 2023 · Dec 31derived | — | — | — | −$9.9M | −$8.9M | — | -0.21 | −$6.1M | $24K | −$6.1M | Mar 24 |
| Q3 2023 · Sep 30 | — | — | — | −$6.1M | −$5.4M | — | -0.15 | −$4.8M | $0 | −$4.8M | Nov 13 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$58.1M | −$84M | — | -1.68 | −$41.4M | $352K | −$41.8M | — | — |
| FY2024 · to Dec 31 | — | — | −$57.3M | −$56.8M | — | -1.31 | −$31.9M | $257K | −$32.2M | — | — |
| FY2023 · to Dec 31 | — | — | −$34.6M | −$31.4M | — | -0.84 | −$18.3M | $160K | −$18.5M | — | — |
| FY2022 · to Dec 31 | — | — | −$52M | −$51.7M | — | -1.54 | −$44M | $133K | −$44.2M | — | — |
| FY2021 · to Dec 31 | — | — | −$90.3M | −$89.9M | — | -3.03 | −$62.9M | $180K | −$63.1M | — | — |
| FY2020 · to Dec 31 | — | — | −$78.9M | −$76.8M | — | -2.63 | −$50.8M | $52K | −$50.9M | — | — |
Every number comes from IRulya Therapeutics Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.